Latest China News

Merino & Co cut its FY2026 loss by 20% as China revenue more than doubled, but group revenue declined and cash reserves fell sharply. The auditor highlighted a material uncertainty over the company’s ability to continue as a going concern.

Everlast Minerals has completed its first export shipment from Bangladesh, but the 109-tonne cargo remains a pilot-scale milestone rather than proof of commercial production. The ASX-listed company ended FY26 with $3.32 million in cash, a $3.03 million loss and commissioning still incomplete at its expanded Gaibandha operation.

EcoGraf’s underwritten share purchase plan raised $3.552 million, well above its $2 million target, after shareholders applied for the full oversubscription. The result gives the company additional funding while leaving the final issue price and dilution to be confirmed.

Compumedics Limited (ASX:CMP) returned to profit in FY26 as record revenue, stronger cash generation and a sharp rise in MEG and SaaS sales reshaped its earnings profile. The company enters FY27 with A$28.3 million of open orders, but lower gross margins and uneven US and European execution remain key tests.

Firebird Metals is moving from manganese exploration towards downstream battery materials, with its Perth demonstration plant backed by a A$2 million ARENA grant. But the ASX-listed company remains loss-making, has A$3.61 million in cash and faces a material uncertainty over its ability to continue without further funding.

Cettire returned to positive operating cash flow in FY26, but its annual report carries a material uncertainty over going concern after current liabilities exceeded current assets by A$51.8 million. The luxury e-commerce group also posted an A$8.5 million statutory loss and is relying on working-capital discipline, VAT recoveries and potentially conditional director support.

Key Petroleum reduced its FY2026 loss, but the oil and gas explorer continues to rely on equity funding while awaiting Queensland Government decisions on ATP 920 and ATP 924. An auditor’s unmodified opinion still highlights material uncertainty over the company’s ability to continue as a going concern.

Argent BioPharma has secured exclusive commercialisation rights to selected Tollovir, Tollovid and NutraVir antiviral products in a worldwide deal excluding China. The agreement adds a new commercial pillar alongside CimetrA®, but does not itself grant pharmaceutical development rights or establish clinical efficacy.

Delegat Group delivered record operating earnings and cash flow in FY26, but reported profit fell after a NZ$8.7 million impairment and other fair-value adjustments. The NZX-listed wine company is forecasting higher case sales and operating NPAT of NZ$62 million to NZ$66 million for FY27.

Synlait’s operational recovery gathered pace in the second half, but the NZX-listed dairy processor still reported a NZ$75.4 million FY26 loss and negative operating cash flow. KPMG flagged a material uncertainty over going concern as the company prepares to refinance facilities due in 2027.

First Graphene expanded its product range and international footprint in FY2026, lifting revenue while narrowing its annual loss. But the company says continued operations depend on securing further equity funding, putting commercial execution and liquidity at the centre of its next phase.

Global X China Tech ETF reported an AUD15.727 million profit for the year ended 30 June 2026, powered by gains in listed Chinese technology investments. But the fund disclosed that its net asset value has since fallen by more than 10%, leaving the audited result looking increasingly historical.